GE HealthCare Gets FDA Approval of Flyrcado to Diagnose Coronary Heart Disease
By Stephen Nakrosis
GE HealthCare has received approval for Flyrcado, its enhanced diagnosis tool for coronary heart disease, from the Food and Drug Administration.
The company said on Friday that Flyrcado, or flurpiridaz F 18, injection is a radiotracer that assists in the diagnosis of the disease.
Since it can be manufactured in an offsite pharmacy and delivered as a ready-to-use unit dose, Flyrcado it has the potential to expand clinician and patient access to PET MPI, GE HealthCare said.
Flyrcado has a half-life of 109-minutes, which is longer than existing PET MPI tracers, and can enable combining exercise stress testing with cardiac PET imaging for CAD, according to the company.
Flyrcado will be available in initial U.S. markets early next year.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 27, 2024 17:13 ET (21:13 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
United States